Skip to main content
SpringerLink
Log in

Androgen Deprivation Therapy in Combination with Radical Prostatectomy

  • Chapter
  • First Online:
Hormone Therapy and Castration Resistance of Prostate Cancer

  • 579 Accesses

Abstract

Radical prostatectomy (RP) is one of the treatment options for patients with localized prostate cancer (PCa). The biochemical recurrence rates in patients with high-risk PCa who underwent RP alone remain high. To date, the clinical benefit, especially with respect to survival, of neoadjuvant therapies, including androgen deprivation therapy (ADT) or chemotherapy, remains unclear. Several prospective, randomized controlled trials showed higher rates of organ-confined disease, reduced rates of extracapsular extension, and reduced rates of positive surgical margins. Although the patients who received neoadjuvant ADT achieved better local tumor control, there were no differences in overall survival (OS) or biochemical recurrence-free survival (BRFS). Patients with locally advanced or seminal vesicle invasion PCa who underwent adjuvant ADT after RP achieved improved 10-year BRFS, local recurrence-free survival, systemic progression-free survival, and cancer-specific survival. However, there was no significant difference in OS. On the contrary, the BRFS rate was higher in high-risk PCa patients treated with neoadjuvant chemohormonal therapy (CHT) than in those treated with RP alone. Neoadjuvant CHT with subsequent RP might reduce the risk of biochemical recurrence.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gleave ME, Goldenberg SL, Chin JL, et al. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol. 2001;166:500–6.

    Article  CAS  Google Scholar 

  2. Lester-Coll NH, Goldhaber SZ, Sher DJ, et al. Death from high-risk prostate cancer versus cardiovascular mortality with hormone therapy. Cancer. 2013;119:1808–15.

    Article  Google Scholar 

  3. Yuh B, Artibani W, Heidenreich A, et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: a systematic review. Eur Urol. 2013;65:918–27.

    Article  Google Scholar 

  4. Yossepowitch O, Eggener SE, Serio AM, et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur Urol. 2008;53:950–9.

    Article  Google Scholar 

  5. Loeb S, Schaeffer EM, Trock BJ, et al. What are the outcomes of radical prostatectomy for high-risk prostate cancer? Urology. 2010;76:710–4.

    Article  Google Scholar 

  6. Mason MD, Parulekar WR, Sydes MR, et al. Final report of the intergroup randomized study of combined androgen-deprivation therapy plus radiotherapy versus androgen-deprivation therapy alone in locally advanced prostate cancer. J Clin Oncol. 2015;33:2143–50.

    Article  Google Scholar 

  7. Widmark A, Klepp O, Solberg A, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomized phase III trial. Lancet. 2009;373:301–8.

    Article  CAS  Google Scholar 

  8. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.

    Article  CAS  Google Scholar 

  9. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–674.

    Article  CAS  Google Scholar 

  10. Benedetti PP, Bellati F, et al. An update in neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol. 2007;107:s20–2.

    Article  Google Scholar 

  11. Soloway MS, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol. 2002;167:112–6.

    Article  Google Scholar 

  12. Klotz LH, Goldenberg SL, Jewett MA, et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol. 2003;170:791–4.

    Article  CAS  Google Scholar 

  13. Shelley MD, Kumar S, Wilt T, et al. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009;35:9–17.

    Article  CAS  Google Scholar 

  14. O’Shaughnessy MJ, Jarosek SL, Virnig BA, et al. Factors associated with reduction in use of neoadjuvant androgen suppression therapy before radical prostatectomy. Urology. 2013;81:745–51.

    Article  Google Scholar 

  15. Braga-Basaria M, Dobs AS, Muller DC, et al. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy. J Clin Oncol. 2006;24:3979–83.

    Article  Google Scholar 

  16. Keating NL, O’Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24:4448–56.

    Article  CAS  Google Scholar 

  17. Narita S, Tsuchiya N, Kumazawa T, et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol. 2012;10:1.

    Article  Google Scholar 

  18. Koie T, Ohyama C, Yamamoto H, et al. Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study. Prostate Cancer Prostatic Dis. 2012;15:397–401.

    Article  CAS  Google Scholar 

  19. Koie T, Mitsuzuka K, Yoneyama T, et al. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. Int J Clin Oncol. 2015;20:1018–25.

    Article  CAS  Google Scholar 

  20. Hagiwara K, Koie T, Ohyama C. Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. Int Urol Nephrol. 2017;49:811–6.

    Article  CAS  Google Scholar 

  21. Joung JY, Kim JE, Kim SH, et al. The prevalence and outcomes of pT0 disease after neoadjuvant hormonal therapy and radical prostatectomy in high-risk prostate cancer. BMC Urol. 2015;15:82.

    Article  Google Scholar 

  22. Köllermann J, Caprano J, Budde A, et al. Follow-up of nondetectable prostate carcinoma (pT0) after prolonged PSA-monitored neoadjuvant hormonal therapy followed by radical prostatectomy. Urology. 2003;62:476–80.

    Article  Google Scholar 

  23. Köllermann J, Hopfenmüller W, Caprano J. Prognosis of stage pT0 after prolonged neoadjuvant endocrine therapy of prostate cancer: a matched-pair analysis. Eur Urol. 2004;45:42–5.

    Article  Google Scholar 

  24. Brown JA, Garlitz C, Strup SE, et al. Laparoscopic radical prostatectomy after neoadjuvant hormonal therapy: an apparently safe and effective procedure. J Laparoendosc Adv Surg Tech A. 2004;14:335–8.

    Article  Google Scholar 

  25. Williams SB, Davis JW, Wang X, et al. Neoadjuvant systemic therapy before radical prostatectomy in high-risk prostate cancer does not increase surgical morbidity: contemporary results using the Clavien system. Clin Genitourin Cancer. 2016;14:130–8.

    Article  Google Scholar 

  26. Hou CP, Lee WC, Lin YH, et al. Neoadjuvant hormone therapy following treatment with robotic-assisted radical prostatectomy achieved favorable in high-risk prostate cancer. Onco Targets Ther. 2015;8:15–9.

    CAS  PubMed  Google Scholar 

  27. Wirth MP, Weissbach L, Marx FJ, et al. Prospective randomized trial comparing flutamide as adjuvant treatment versus observation after radical prostatectomy for locally advanced, lymph node-negative prostate cancer. Eur Urol. 2004;45:2672–0.

    Article  Google Scholar 

  28. Siddiqui SA, Boorjian SA, Blute ML, et al. Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. BJU Int. 2011;107:383–8.

    Article  Google Scholar 

  29. Moschini M, Sharma V, Gandaglia G, et al. Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. BJU Int. 2017;120:69–75.

    Article  CAS  Google Scholar 

  30. Schulman CC, Debruyne FM, Forster G, et al. 4-year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol. 2000;38:706–13.

    Article  CAS  Google Scholar 

  31. Dalkin BL, Ahmann FR, Nagle R, et al. Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol. 1996;155:1357–60.

    Article  CAS  Google Scholar 

  32. Prezioso D, Lotti T, Polito M, et al. Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int. 2004;72:189–95.

    Article  CAS  Google Scholar 

  33. Labrie F, Cusan L, Gomez JL, et al. Neoadjuvant hormonal therapy: the Canadian experience. Urology. 1997;49:56–64.

    Article  CAS  Google Scholar 

  34. Selli C, Montironi R, Bono A, et al. Effects of complete androgen blockade for 12 and 24 weeks on the pathological stage and resection margin status of prostate cancer. J Clin Pathol. 2002;55:508–13.

    Article  CAS  Google Scholar 

  35. van der Kwast TH, Têtu B, Candas B, et al. Prolonged neoadjuvant combined androgen blockade leads to a further reduction of prostatic tumor volume: three versus six months of endocrine therapy. Urology. 1999;53:523–9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan

    Takuya Koie & Chikara Ohyama

Authors
  1. Takuya Koie
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Chikara Ohyama
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Takuya Koie .

Editor information

Editors and Affiliations

  1. Department of Urology, Tohoku University School of Medicine, Sendai, Japan

    Yoichi Arai

  2. Department of Urology, Kyoto University Graduate School of Medicine, Kyoto, Japan

    Osamu Ogawa

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Koie, T., Ohyama, C. (2018). Androgen Deprivation Therapy in Combination with Radical Prostatectomy. In: Arai, Y., Ogawa, O. (eds) Hormone Therapy and Castration Resistance of Prostate Cancer. Springer, Singapore. https://doi.org/10.1007/978-981-10-7013-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-7013-6_11

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-7012-9

  • Online ISBN: 978-981-10-7013-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation